Showing 4811-4820 of 5771 results for "".
- Vision Expo East Cancelled Due to Coronavirus; Will Consolidate With Vision Expo West in Las Vegashttps://modernod.com/news/vision-expo-east-cancelled-due-to-coronavirus-will-consolidate-with-vision-expo-west-in-las-vegas/2477359/The organizers of Vision Expo announced that they are cancelling the scheduled Vision Expo East meeting scheduled to take place in New York, March 26-29, and consolidate that meeting with Vision Expo West in Las Vegas, Sept. 23-26. The decision was made due to concerns over the spread of the coro
- Nicox’s End-of-Phase 2 Meeting With the FDA Sets Stage for NCX 470 Phase 3 Program in Glaucomahttps://modernod.com/news/nicoxs-end-of-phase-2-meeting-with-the-fda-sets-stage-for-ncx-470-phase-3-program-in-glaucoma/2477350/Nicox announced that it has successfully completed an end-of-phase 2 meeting with the FDA and agreed on the design for the NCX 470 phase 3 program, as well as nonclinical and CMC plans supporting submission of a new drug application (NDA) in the U.S. NCX 470, a novel second generation nitric oxid
- Allergan Receives FDA Approval for Durysta, the First Sustained-Release Implant for Glaucomahttps://modernod.com/news/allergan-receives-fda-approval-for-durysta-the-first-sustained-release-implant-for-glaucoma/2477351/Allergan announced that the FDA has approved the company’s new drug application (NDA) for Durysta (bimatoprost implant) 10 mcg for intracameral administration. With this approval, Durysta becomes the first intracameral, biodegradable sustained-release implant indicated to reduce IOP in pati
- Nature Gene Therapy Publishes Preclinical Data of Ocugen’s OCU400 Genetic Modifier to Treat Retinitis Pigmentosahttps://modernod.com/news/nature-gene-therapy-publishes-preclinical-data-of-ocugens-ocu400-genetic-modifier-to-treat-retinitis-pigmentosa/2477345/Ocugen announced the publication in Nature Gene Therapy of preclinical data of nuclear hormone receptor gene NR2E3 as a genetic modifier and therapeutic agent to treat multiple retinal degenerative diseases. OCU400 (NR2E3-AAV) has received two orphan drug designatio
- EMA Grants Two Product Designations to Janssen’s RPGR Gene Therapy for X-Linked Retinitis Pigmentosahttps://modernod.com/news/ema-grants-two-product-designations-to-janssens-rpgr-gene-therapy-for-x-linked-retinitis-pigmentosa/2477338/The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Medicines Agency (EMA) has granted both PRIME (PRIority MEdicines) and Advanced Therapy Medicinal Product (ATMP) designations to the company’s adeno-associated virus (AAV)-RPGR gene t
- Eyevance Pharmaceuticals launches Tobradex ST in the United Stateshttps://modernod.com/news/eyevance-pharmaceuticals-launches-tobradex-st-in-the-united-states/2477333/Eyevance Pharmaceuticals has announced the US launch of Tobradex ST (tobramycin/dexamethasone ophthalmic suspension) 0.3%/0.05% following the company’s acquisition of the product in late 2019. Tobradex ST is an FDA approved, fixed-dose topical antibiotic and corticosteroid combination indicated f
- The American Optometric Association (AOA) Partners With Lyft To Offer Free Rides To Get A Comprehensive Eye Examhttps://modernod.com/news/the-american-optometric-association-aoa-partners-with-lyft-to-offer-free-rides-to-get-a-comprehensive-eye-exam/2477334/The American Optometric Association (AOA), the leading authority on quality care and an advocate for our nation’s health, representing more than 30,000 doctors of optometry, announced that it is working with Lyft, the transportation network, to offer free rides to people in select cities in
- Graybug Vision Presents Preclinical Results for Glaucoma Drug Candidate GB-401https://modernod.com/news/graybug-vision-presents-preclinical-results-for-glaucoma-drug-candidate-gb-401/2477332/Graybug Vision presented preclinical study results for GB-401, a novel injectable depot formulation of a proprietary beta-adrenergic antagonist prodrug, as a potential sustained-delivery treatment of up to 6 months for primary open angle glaucoma (POAG), at the American Glaucoma Society annual me
- VEO Ophthalmics to Support The Masket Foundation to Raise Awareness of Aniridiahttps://modernod.com/news/veo-ophthalmics-to-support-the-masket-foundation-to-raise-awareness-of-aniridia/2477331/VEO Ophthalmics announced that, in honor of Rare Disease Day, it is collaborating with the Masket Foundation to raise awareness of aniridia and treatment options for aniridia. Aniridia is a serious ophthalmic rare disease in which a patient’s iris does not develop properly. VEO Ophthalmics is the
- Iridex Launches Revised MicroPulse P3 Device for Glaucomahttps://modernod.com/news/iridex-launches-revised-micropulse-p3-device-for-glaucoma/2477328/Iridex announced the introduction of the second generation of the MicroPulse P3 Device, which has been redesigned to deliver greater stability, visualization, coupling, and fit, according to a company news release. “The revised MicroPulse P3 Device is intuit